TriangleNCT00003816 · OUTCOME
4 Year PFS
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percentage of participants
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 4 years
What was measured
progression free survival estimate at 4 years post BMT (events are disease progression/relapse and death due to any cause)
Groups in this outcome
BuCy
Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. busulfan: Given IV cyclophosphamide: Given IV
CyTBI
Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1. cyclophosphamide: Given IV total-body irradiation: Given twice daily for 3 days
FluMel
Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2. fludarabine phosphate: Given IV melphalan: Given IV
VpCyTBI
Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1. cyclophosphamide: Given IV etoposide: Given IV total-body irradiation: Given twice daily for 3 days
Other
Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1. OR Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3. OR Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4. OR Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2. OR Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
| Group | Source count |
|---|---|
| BuCy | 55 |
| CyTBI | 69 |
| FluMel | 199 |
| VpCyTBI | 23 |
| Other | 15 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| BuCy | 49.1 | Not reported | 36 | 62.2 | Not reported |
| CyTBI | 52.2 | Not reported | 40.4 | 64 | Not reported |
| FluMel | 33.2 | Not reported | 26.7 | 39.7 | Not reported |
| VpCyTBI | 26.1 | Not reported | 8.1 | 44.1 | Not reported |
| Other | 40 | Not reported | 15.3 | 64.7 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 36
- upper Limit
- 62.2
- value
- 49.1
- group Id
- OG001
- lower Limit
- 40.4
- upper Limit
- 64
- value
- 52.2
- group Id
- OG002
- lower Limit
- 26.7
- upper Limit
- 39.7
- value
- 33.2
- group Id
- OG003
- lower Limit
- 8.1
- upper Limit
- 44.1
- value
- 26.1
- group Id
- OG004
- lower Limit
- 15.3
- upper Limit
- 64.7
- value
- 40
- denoms
- counts
- group Id
- OG000
- value
- 55
- group Id
- OG001
- value
- 69
- group Id
- OG002
- value
- 199
- group Id
- OG003
- value
- 23
- group Id
- OG004
- value
- 15
- units
- Participants
- description
- progression free survival estimate at 4 years post BMT (events are disease progression/relapse and death due to any cause)
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive busulfan IV over 2 hours every 6 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2. busulfan: Given IV cyclophosphamide: Given IV
- id
- OG000
- title
- BuCy
- description
- Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and total-body irradiation (TBI) twice daily on days -3 to -1. cyclophosphamide: Given IV total-body irradiation: Given twice daily for 3 days
- id
- OG001
- title
- CyTBI
- description
- Patients receive fludarabine IV over 30 minutes on days -6 to -2 and melphalan IV over 1 hour on days -3 and -2. fludarabine phosphate: Given IV melphalan: Given IV
- id
- OG002
- title
- FluMel
- description
- Patients receive etoposide IV over 26 hours beginning on day -5, cyclophosphamide IV over 2 hours on day -4, and TBI twice daily on days -3 to -1. cyclophosphamide: Given IV etoposide: Given IV total-body irradiation: Given twice daily for 3 days
- id
- OG003
- title
- VpCyTBI
- description
- Patients receive cyclophosphamide IV over 2 hours on days -5 and -4, TBI twice daily on days -3 to -1, and anti-thymocyte globulin IV over 4-8 hours on days -3 to -1. OR Patients receive cyclophosphamide IV over 2 hours on days -5 to -2 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -3. OR Patients receive cyclophosphamide IV over 24 hours, carboplatin IV over 24 hours, and thiotepa IV over 24 hours on days -7 to -4. OR Patients receive fludarabine IV over 30 minutes on days -5 to -1 and anti-thymocyte globulin IV over 4-8 hours on days -5 to -2. OR Patients receive busulfan IV over 2 hours every 6 hours and anti-thymocyte globulin IV over 4-8 hours on days -7 to -4 and cyclophosphamide IV over 2 hours on days -3 and -2.
- id
- OG004
- title
- Other
- param Type
- NUMBER
- reporting Status
- POSTED
- time Frame
- 4 years
- title
- 4 Year PFS
- type
- SECONDARY
- unit Of Measure
- percentage of participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice